Comparative in vitro susceptibility of Burkholderia pseudomallei to doripenem, ertapenem, tigecycline and moxifloxacin

Harris, Patrick, Engler, Cathy and Norton, Robert (2011) Comparative in vitro susceptibility of Burkholderia pseudomallei to doripenem, ertapenem, tigecycline and moxifloxacin. International Journal of Antimicrobial Agents, 37 6: 547-549. doi:10.1016/j.ijantimicag.2011.02.001


Author Harris, Patrick
Engler, Cathy
Norton, Robert
Title Comparative in vitro susceptibility of Burkholderia pseudomallei to doripenem, ertapenem, tigecycline and moxifloxacin
Formatted title
Comparative in vitro susceptibility of Burkholderia pseudomallei to doripenem, ertapenem, tigecycline and moxifloxacin
Journal name International Journal of Antimicrobial Agents   Check publisher's open access policy
ISSN 0924-8579
1872-7913
Publication date 2011-06
Year available 2011
Sub-type Letter to editor, brief commentary or brief communication
DOI 10.1016/j.ijantimicag.2011.02.001
Open Access Status Not yet assessed
Volume 37
Issue 6
Start page 547
End page 549
Total pages 3
Place of publication Amsterdam, Netherlands
Publisher Elsevier BV
Language eng
Formatted abstract
Burkholderia pseudomallei, the causative agent of melioidosis, continues to present therapeutic challenges in endemic areas. A number of clinical issues have prompted consideration of alternative antimicrobial therapies. These include stability in 24-h infusion pumps, broad-spectrum coverage in the empirical treatment of community-acquired pneumonia, cost, the need for effective oral agents and rare reports of emerging resistance. This study aimed to examine the in vitro susceptibility of B. pseudomallei to four new antimicrobial agents, namely moxifloxacin, tigecycline, ertapenem and doripenem. A total of 100 clinical isolates were tested by Etest and disk diffusion. As there are no interpretative standards for these antimicrobials, MIC90 values (minimum inhibitory concentrations for 90% of the isolates) were compared with those for meropenem. MIC values for each agent were correlated with zone of inhibition diameters. MICs for doripenem were broadly similar to those for meropenem, with a MIC90 of 1.5 μg/mL (range 0.38-4 μg/mL). There was good correlation (r = -0.71; P < 0.001) between the MIC and disk diffusion for doripenem. Ertapenem, tigecycline and moxifloxacin had limited in vitro activity in this study, although no interpretative criteria exist for these agents. Further in vitro, animal and clinical studies are suggested to validate the efficacy of doripenem in the management of melioidosis.
Keyword Carbapenem
Disk diffusion
Etest
Fluoroquinolone
Glycylcycline
Melioidosis
Q-Index Code CX
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Letter to editor, brief commentary or brief communication
Collection: School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 5 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 9 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Mon, 15 Dec 2014, 12:43:10 EST by Ms Kate Rowe on behalf of Learning and Research Services (UQ Library)